anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.86, 0.96]< 121%67 studies (67/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.79 [0.50, 1.24]< 10%2 studies (2/-)84.9 %some concernnot evaluable moderatecrucial-
deaths 0.89 [0.85, 0.93]< 121%108 studies (108/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.83 [0.72, 0.96]< 127%19 studies (19/-)99.4 %some concernlow moderatecrucial-
clinical deterioration 0.71 [0.58, 0.86]< 149%21 studies (21/-)100.0 %some concernlow moderateimportant-
clinical improvement 1.15 [1.06, 1.25]> 137%30 studies (30/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.31 [1.06, 1.62]> 142%9 studies (9/-)99.3 %lowserious highimportant-
clinical improvement (28-day) 1.48 [1.08, 2.03]> 144%11 studies (11/-)99.3 %some concerncritical moderateimportant-
clinical improvement (7-day) 1.29 [0.82, 2.01]> 161%5 studies (5/-)86.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.11 [1.01, 1.21]> 115%14 studies (14/-)98.9 %some concerncritical moderateimportant-
death or ventilation 0.90 [0.85, 0.96]< 153%26 studies (26/-)100.0 %some concerncritical moderateimportant-
hospital discharge 1.07 [1.00, 1.14]> 159%13 studies (13/-)97.6 %some concerncritical moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
mechanical ventilation 0.87 [0.79, 0.95]< 123%30 studies (30/-)99.8 %some concerncritical moderateimportant1
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 3.02 [1.77, 5.14]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
viral clearance 2.50 [1.05, 5.93]> 185%7 studies (7/-)98.1 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.18 [0.54, 2.54]> 183%2 studies (2/-)66.0 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.08 [0.07, 16.52]> 197%5 studies (5/-)52.2 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.59 [0.67, 3.76]> 173%4 studies (4/-)85.4 %some concernnot evaluable moderateimportant-
ICU admission 0.76 [0.60, 0.96]< 10%13 studies (13/-)98.9 %some concernlow moderatenon important-
recovery 1.17 [0.98, 1.39]> 125%7 studies (7/-)96.2 %lownot evaluable highnon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %NAnot evaluable important-
related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 1.04 [0.90, 1.20]< 122%24 studies (24/-)31.6 %some concernlow moderateimportant-
superinfection 0.70 [0.46, 1.07]< 153%4 studies (4/-)95.0 %lownot evaluable highimportant-
adverse events 1.23 [1.01, 1.49]< 124%19 studies (19/-)1.9 %some concernlow moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.